Royalty Pharma plc

NasdaqGS:RPRX Stock Report

Market Cap: US$14.7b

Royalty Pharma Valuation

Is RPRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RPRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RPRX ($24.92) is trading below our estimate of fair value ($172.29)

Significantly Below Fair Value: RPRX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RPRX?

Key metric: As RPRX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RPRX. This is calculated by dividing RPRX's market cap by their current earnings.
What is RPRX's PE Ratio?
PE Ratio9.7x
EarningsUS$1.15b
Market CapUS$14.68b

Price to Earnings Ratio vs Peers

How does RPRX's PE Ratio compare to its peers?

The above table shows the PE ratio for RPRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.5x
JAZZ Jazz Pharmaceuticals
16.1x16.3%US$7.4b
ELAN Elanco Animal Health
28x1.6%US$5.7b
OGN Organon
2.9x-8.3%US$3.8b
PBH Prestige Consumer Healthcare
18.9x5.3%US$3.9b
RPRX Royalty Pharma
9.7x6.3%US$14.7b

Price-To-Earnings vs Peers: RPRX is good value based on its Price-To-Earnings Ratio (9.7x) compared to the peer average (16.5x).

Price to Earnings Ratio vs Industry

How does RPRX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

9 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
2.9x-8.3%US$3.75b
NDOI Endo
0.5xn/aUS$1.83b
KPRX Kiora Pharmaceuticals
1.8x-40.4%US$9.81m
EDXC Endexx
0.8xn/aUS$5.57m
RPRX 9.7xIndustry Avg. 16.7xNo. of Companies9PE01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RPRX is good value based on its Price-To-Earnings Ratio (9.7x) compared to the US Pharmaceuticals industry average (16.7x).

Price to Earnings Ratio vs Fair Ratio

What is RPRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RPRX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9.7x
Fair PE Ratio23.9x

Price-To-Earnings vs Fair Ratio: RPRX is good value based on its Price-To-Earnings Ratio (9.7x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RPRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$24.92
US$41.53
+66.6%
17.8%US$51.00US$28.00n/a10
Dec ’25US$26.66
US$41.53
+55.8%
17.8%US$51.00US$28.00n/a10
Nov ’25US$27.10
US$41.43
+52.9%
17.9%US$51.00US$28.00n/a10
Oct ’25US$28.38
US$44.75
+57.7%
20.1%US$60.00US$28.00n/a8
Sep ’25US$29.03
US$44.75
+54.2%
20.1%US$60.00US$28.00n/a8
Aug ’25US$28.49
US$45.38
+59.3%
20.5%US$60.00US$28.00n/a8
Jul ’25US$26.19
US$45.00
+71.8%
20.2%US$60.00US$28.00n/a8
Jun ’25US$27.41
US$45.75
+66.9%
15.7%US$60.00US$37.00n/a8
May ’25US$28.07
US$45.40
+61.7%
15.4%US$60.00US$37.00n/a9
Apr ’25US$29.90
US$45.40
+51.8%
15.0%US$60.00US$37.00n/a9
Mar ’25US$29.93
US$45.40
+51.7%
15.0%US$60.00US$37.00n/a9
Feb ’25US$28.68
US$46.33
+61.6%
16.3%US$60.00US$37.00n/a9
Jan ’25US$28.09
US$46.50
+65.5%
15.7%US$60.00US$37.00n/a8
Dec ’24US$27.35
US$47.88
+75.0%
16.9%US$60.00US$37.00US$26.668
Nov ’24US$27.23
US$48.50
+78.1%
14.5%US$60.00US$40.00US$27.108
Oct ’24US$27.14
US$49.44
+82.2%
14.8%US$60.00US$40.00US$28.389
Sep ’24US$30.27
US$49.64
+64.0%
14.5%US$60.00US$40.00US$29.039
Aug ’24US$30.90
US$50.42
+63.2%
12.2%US$60.00US$42.00US$28.499
Jul ’24US$30.74
US$51.58
+67.8%
11.4%US$60.00US$42.00US$26.1910
Jun ’24US$33.17
US$51.58
+55.5%
11.4%US$60.00US$42.00US$27.4110
May ’24US$35.33
US$52.08
+47.4%
11.3%US$60.00US$42.00US$28.0710
Apr ’24US$36.03
US$52.53
+45.8%
8.9%US$60.00US$47.00US$29.909
Mar ’24US$35.62
US$52.53
+47.5%
8.9%US$60.00US$47.00US$29.939
Feb ’24US$38.90
US$53.38
+37.2%
7.5%US$60.00US$47.00US$28.6810
Jan ’24US$39.52
US$54.07
+36.8%
6.4%US$60.00US$49.80US$28.0911
Dec ’23US$44.04
US$54.35
+23.4%
6.1%US$60.00US$49.80US$27.3511

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:43
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Royalty Pharma plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Charlie YangBofA Global Research
Jason Matthew GerberryBofA Global Research